IHC with the Ki67 antibody demonstrated that the in vivo proliferation of rectal adenocarcinoma cells was decreased in the TIPE2 group compared with the Mock group and increased in the sh‐TIPE2 group compared with the sh‐Scb group. This evidence concerns the gene MKI67 and rectum adenocarcinoma.